Semaglutide vs. Tirzepatide: What’s the Difference?

Compare tirzepatide and semaglutide, two medications approved for type 2 diabetes, with some versions approved for weight management. Connect with a licensed medical provider to explore treatment options.

Key takeaways
  • Both medications are approved for type 2 diabetes; specific versions are also approved for weight management.
  • Semaglutide acts on the GLP-1 receptor, while tirzepatide targets both GIP and GLP-1 receptors.
  • Clinical trials have evaluated weight changes associated with each medication, but individual results vary.
  • Both are once-weekly injectables with differing dosing protocols.
  • Common side effects include nausea and gastrointestinal symptoms.
  • Insurance coverage depends on the specific drug and the diagnosis provided by a healthcare provider.

Semaglutide and tirzepatide are medications originally developed for managing blood sugar in adults with type 2 diabetes. In recent years, specific formulations, Wegovy® and Zepbound™, have also received FDA approval for chronic weight management in certain individuals with obesity or overweight and at least one weight-related condition.

In this article, we’ll explore how these two medications compare in terms of mechanism of action, dosing, side effects, and what recent clinical studies have shown. This information can help guide more informed discussions with licensed healthcare providers.

Disclaimer: Eden is not a pharmacy or medical provider. Eden connects patients with independent licensed healthcare professionals who evaluate treatment options. All medical decisions, including prescriptions, are made solely by licensed providers. Medications, when prescribed, are filled through state-licensed pharmacies.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

Mechanism of Action

Semaglutide

Semaglutide is a GLP-1 receptor agonist, which means it mimics the hormone GLP-1 to help regulate blood sugar by:

  • Enhancing insulin secretion (when glucose levels are high)
  • Reducing glucagon secretion
  • Slowing gastric emptying
  • Supporting appetite regulation

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it works on two hormone pathways involved in glucose and metabolic regulation. This dual mechanism is under investigation for its potential to impact both glycemic control and weight management outcomes.

Efficacy in Weight Management

Weight Management Outcomes

Semaglutide (Wegovy®):
In the STEP 1 trial, adults with overweight or obesity taking 2.4 mg weekly of semaglutide experienced a mean weight loss of 14.9% over 68 weeks.

Tirzepatide (Zepbound™):
In the SURMOUNT-1 trial, participants receiving 15 mg weekly of tirzepatide lost up to 22.5% of their body weight over 72 weeks.

Note: These results are averages from large clinical trials. Outcomes vary by individual and are influenced by baseline health, lifestyle, and adherence. Ozempic and Mounjaro are not FDA-approved for weight loss. Wegovy and Zepbound are the approved formulations.

Glycemic Control

Both medications have been shown to reduce HbA1c (a marker of blood sugar control):

Side Effects

The most commonly reported side effects of both medications include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Fatigue
  • Injection site reactions

Licensed medical providers may recommend dose titration (starting with a lower dose and gradually increasing) to reduce the risk of side effects. It’s important to follow provider guidance for the best outcomes.

Dosing and Administration

Medication Starting Dose Maximum Dose Frequency
Semaglutide (Wegovy®) 0.25 mg/week 2.4 mg/week Weekly
Tirzepatide (Zepbound™) 2.5–5 mg/week 15 mg/week Weekly

Only a licensed healthcare provider can determine the correct dosing schedule and whether treatment is appropriate.

Cost and Access

Medication pricing and insurance coverage vary widely depending on:

  • The brand prescribed (e.g., Ozempic®, Wegovy®, Mounjaro®, Zepbound™)
  • Whether the diagnosis qualifies for insurance coverage (e.g., type 2 diabetes vs. weight-related conditions)
  • The patient's insurance plan

Eden helps patients connect with independent licensed medical providers who can determine eligibility and, if appropriate, prescribe treatment. Any prescribed medications are fulfilled through state-licensed compounding pharmacies or third-party pharmacy partners.

Conclusion

While semaglutide and tirzepatide share some similarities, they are distinct medications with different mechanisms of action, dosing schedules, and clinical outcomes. If you’re curious about your options, the best next step is to speak with a licensed healthcare provider who can evaluate your individual health goals and determine whether you’re a candidate for treatment.

This article is for educational purposes only and does not constitute medical advice. Eden does not provide treatment or prescribe medication. Only a licensed medical provider can determine if you qualify for therapy.

Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.

Frequently asked questions

GLP-1 Treatments
Personalized doctor-led plans
As low as $196/mo*
Get started
Important safety information
Important safety information
Verified Customer
"I had an incredible experience, and the support that Eden provides is 10/10"
Kerstin
Verified Customer
“I had so many questions in the beginning, and both the doctor and customer support were so patient and thorough.”
Lane L.

Is GLP-1 Treatments right for you?

Is GLP-1 Treatments right for you?

Get started

References

Capehorn, M., Ghani, Y., Hindsberger, C., Johansen, P., & Jódar, E. (2020). Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10. Diabetes Therapy, 11(5), 1061–1075. https://doi.org/10.1007/s13300-020-00796-z

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038

Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Landó, L. F., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/s0140-6736(21)01324-6

Wen, J., Syed, B., Nadora, D., How‐Volkman, C., Bernstein, E., Truong, A., Akhtar, M., Razick, A., Puglisi, J., & Frezza, E. (2025). Tirzepatide versus Semaglutide on Weight Loss in Type 2 diabetes patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies. Endocrinology Diabetes & Metabolism, 8(3). https://doi.org/10.1002/edm2.70045

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183